Penumbra, Inc.

Penumbra, Inc.

PENยทNYSE

$319.37

+0.20%
HealthcareMedical - Devices

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

At a Glance

Live Snapshot
Market Cap$12.56B
EPS4.5700
P/E Ratio69.88
Earnings Date08/04/2026
3Y+33.0%
5Y+122.0%
10Y+493.0%
3Y+7.0%
5Y+115.0%
10Y+856.0%
3Y+43.0%
5Y+124.0%
10Y+436.0%
pen

Penumbra, Inc. Funding & Solvency Profile

PEN ยท NYSE
Cash & Cash Equivalents186.90M
Net Receivables190.02M
Inventory431.55M
Other Current Assets408.22M
Total Current Assets1 B
Property, Plant & Equipment317.00M
Goodwill & Intangible Assets172.94M
Long-Term Investments0.00
Other Non-Current Assets119.90M
Total Non-Current Assets437 M
Total Assets
1.83B

Financial Health Analysis

Current Ratio

6.64x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.28x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

1 B

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

67% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Penumbra, Inc. Balance Sheet

PEN โ€ข NYSE

Penumbra, Inc. Balance SheetDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013
ASSETS
CURRENT ASSETS
186.9M
324.4M
167.5M
69.9M
59.4M
69.7M
72.8M
67.9M
50.6M
13.2M
19.5M
3.3M
4.1M
0.0
15.7M
121.7M
118.2M
195.5M
195.2M
116.6M
133M
164M
115.5M
129.3M
48.3M
9.5M
186.9M
340.1M
289.2M
188M
254.9M
264.8M
189.4M
200.9M
214.6M
128.8M
148.8M
51.5M
13.7M
190M
167.7M
201.8M
203.4M
133.9M
114.6M
105.9M
81.9M
58M
43.3M
29.4M
20.6M
13.2M
190M
167.7M
201.8M
203.4M
133.9M
114.6M
105.9M
81.9M
58M
43.3M
29.4M
18.9M
13.1M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
1.7M
78K
431.5M
406.7M
388M
334M
263.5M
219.5M
153M
115.7M
94.9M
73M
56.8M
33.5M
27.1M
0.0
0.0
0.0
0.0
29.2M
18.7M
14.9M
12.2M
14.7M
9.2M
7.4M
3.1M
3.2M
408.2M
36.6M
36.4M
30.3M
0.0
0.0
0.0
0.0
0.0
9.5M
1.3M
6.6M
5.2M
1.2B
951.1M
915.4M
755.7M
681.5M
617.7M
463.1M
410.7M
382.2M
263.8M
244.4M
115.3M
62.2M
NON-CURRENT ASSETS
317M
268.4M
280.5M
280.4M
227.1M
127.4M
135.5M
35.4M
30.9M
21.5M
9M
5.2M
2M
166.8M
165.8M
166.3M
166M
166.4M
8.4M
7.7M
7.8M
8.2M
0.0
0.0
0.0
0.0
6.2M
6.5M
83.1M
91.7M
90.6M
10.6M
25.4M
27.2M
23.8M
0.0
0.0
0.0
0.0
172.9M
172.3M
249.4M
257.8M
257M
19M
33.1M
35.1M
32M
0.0
-5K
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
3.9M
0.0
5K
0.0
6M
0.0
0.0
85.2M
64.2M
65.7M
50.1M
31.3M
32.9M
26.7M
22.5M
10.1M
571K
424K
119.9M
141.3M
25.9M
12.8M
13M
8.7M
2.9M
875K
1M
487K
393K
328K
454K
609.8M
582.1M
640.9M
615.2M
562.8M
205.3M
202.8M
104.3M
94.4M
44.4M
19.5M
6.1M
8.9M
1.8B
1.5B
1.6B
1.4B
1.2B
823M
665.9M
515M
476.7M
308.3M
263.8M
121.4M
71.1M
LIABILITIES
CURRENT LIABILITIES
34.7M
31.3M
27.2M
26.7M
13.4M
14.1M
15.1M
8.2M
6.8M
4.1M
3.4M
3M
1.7M
34.7M
31.3M
27.2M
26.7M
13.4M
14.1M
15.1M
8.2M
6.8M
4.1M
2.6M
2.3M
1.3M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
839K
638K
368K
0.0
0.0
103.6M
97.1M
99.8M
76M
65.8M
48.6M
36M
17M
13.7M
8.2M
5.1M
16.2M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
14.6M
13.4M
12M
10M
6M
8.3M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
907K
839K
638K
368K
0.0
0.0
7M
9.2M
0.0
0.0
0.0
0.0
0.0
344K
526K
1.6M
1.1M
132.2M
112.4M
0.0
0.0
0.0
9.8M
1.8M
9.3M
8.9M
14.4M
10.6M
8M
7.9M
183.1M
158.3M
151.1M
144.9M
123.2M
105.9M
91M
66.1M
51.6M
35.8M
28.1M
20.8M
15.8M
NON-CURRENT LIABILITIES
203.5M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
6M
0.0
0.0
0.0
0.0
0.0
4.8M
4M
4.2M
3.3M
0.0
0.0
0.0
0.0
12.3M
15.1M
5.3M
3.3M
3.6M
3.2M
11.2M
22.4M
21.4M
5.9M
3.2M
112.9M
57.4M
215.8M
223.9M
226.2M
227.1M
167.1M
79.3M
89.2M
26.5M
24.7M
5.9M
3.2M
112.9M
63.4M
0.0
223.4M
234.3M
235.8M
173.5M
77.3M
82.3M
0.0
0.0
0.0
0.0
0.0
0.0
398.9M
382.3M
377.4M
372M
290.3M
185.2M
180.3M
92.6M
76.3M
41.7M
31.3M
133.8M
79.2M
SHAREHOLDERS' EQUITY
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
431K
0.0
263.8M
111.5M
56.2M
39K
38K
39K
38K
37K
36K
35K
34K
33K
31K
30K
5K
4K
0.0
1.1B
1B
963M
910.6M
598.3M
430.7M
415.1M
396.8M
273.9M
252.1M
8.4M
6.3M
237.7M
60M
134.9M
43.9M
45.9M
40.6M
57.5M
9.1M
2M
-2.7M
-17.5M
-19.8M
-15M
4.3M
-5.8M
-3.2M
-8.1M
-2.6M
2.5M
-2.3M
-1.9M
1.6M
-4.7M
-2.1M
-864K
796K
1.2B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-5K
-117K
-138K
1.4B
1.2B
1.2B
998.9M
953.9M
641.5M
485.9M
422.2M
400.4M
266.5M
232.5M
-12.4M
-8.1M
1.4B
1.2B
1.2B
998.9M
953.9M
637.8M
485.6M
422.4M
400.4M
266.5M
232.5M
-12.4M
-8.1M
0.0
0.0
0.0
0.0
0.0
-3.7M
-279K
175K
0.0
0.0
0.0
0.0
0.0
SUMMARY
1.8B
1.5B
1.6B
1.4B
1.2B
823M
665.9M
515M
476.7M
308.3M
263.8M
121.4M
71.1M
0.0
15.7M
121.7M
118.2M
195.5M
195.2M
116.6M
133M
167.8M
115.5M
129.3M
48.3M
15.5M
219.7M
223.4M
234.3M
235.8M
173.5M
77.3M
82.3M
0.0
0.0
0.0
0.0
0.0
6M
32.8M
-101M
66.9M
165.9M
114.2M
7.6M
9.5M
-67.9M
-50.6M
-13.2M
-19.5M
-3.3M
1.9M
39,161,961
39,161,961
39,161,961
39,161,961
39,161,961
39,161,961
39,161,961
39,161,961
39,161,961
39,161,961
39,161,961
39,161,961
39,161,961

SEC Filings

PEN - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 07, 2026
May 06, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 06, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 06, 2026
May 06, 2026
2026
DEF 14A

DEF 14A 2026

N/A

April 29, 2026
June 18, 2026
2026
10-K

10-K 2025 FY

FY

February 25, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 25, 2026
February 25, 2026
2026
8-K

8-K 2026

N/A

January 15, 2026
January 14, 2026
2026
8-K

8-K 2025

N/A

November 05, 2025
November 05, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 05, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

August 27, 2025
August 22, 2025
2025
Showing 1 to 10 of 149 filings